Cantor Fitzgerald L. P. Makes New $1.08 Million Investment in Avalo Therapeutics, Inc. $AVTX

Cantor Fitzgerald L. P. bought a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 85,247 shares of the company’s stock, valued at approximately $1,083,000. Cantor Fitzgerald L. P. owned about 0.47% of Avalo Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. BIT Capital GmbH purchased a new stake in shares of Avalo Therapeutics in the 3rd quarter worth about $25,000. Geode Capital Management LLC increased its holdings in Avalo Therapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after acquiring an additional 2,648 shares in the last quarter. Quadrature Capital Ltd acquired a new position in Avalo Therapeutics during the second quarter worth about $55,000. Dimensional Fund Advisors LP acquired a new position in Avalo Therapeutics during the third quarter worth about $143,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Avalo Therapeutics in the second quarter valued at about $56,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Price Performance

Avalo Therapeutics stock opened at $14.68 on Thursday. The stock has a market capitalization of $271.73 million, a P/E ratio of -2.74 and a beta of 0.84. Avalo Therapeutics, Inc. has a 12-month low of $3.39 and a 12-month high of $20.72. The firm’s 50-day moving average is $15.84 and its two-hundred day moving average is $15.65.

Wall Street Analyst Weigh In

AVTX has been the subject of a number of recent research reports. Guggenheim assumed coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a “buy” rating and a $50.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Avalo Therapeutics in a report on Thursday, January 15th. Finally, Mizuho raised Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Insider Buying and Selling

In other Avalo Therapeutics news, insider Mittie Doyle sold 25,492 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $16.15, for a total value of $411,695.80. Following the completion of the transaction, the insider directly owned 3,622 shares in the company, valued at approximately $58,495.30. The trade was a 87.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 3.03% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.